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BACKGROUND AND PURPOSE
An ever-growing wealth of information on current drugs and their pharmacological effects is available from online databases.
As our understanding of systems biology increases, we have the opportunity to predict, model and quantify how drug
combinations can be introduced that outperform conventional single-drug therapies. Here, we explore the feasibility of such
systems pharmacology approaches with an analysis of the mevalonate branch of the cholesterol biosynthesis pathway.
EXPERIMENTAL APPROACH
Using open online resources, we assembled a computational model of the mevalonate pathway and compiled a set of inhibitors
directed against targets in this pathway. We used computational optimization to identify combination and dose options that
show not only maximal efﬁcacy of inhibition on the cholesterol producing branch but also minimal impact on the geranylation
branch, known to mediate the side effects of pharmaceutical treatment.
KEY RESULTS
We describe serious impediments to systems pharmacology studies arising from limitations in the data, incomplete coverage and
inconsistent reporting. By curating a more complete dataset, we demonstrate the utility of computational optimization for
identifying multi-drug treatments with high efﬁcacy and minimal off-target effects.
CONCLUSION AND IMPLICATIONS
We suggest solutions that facilitate systems pharmacology studies, based on the introduction of standards for data capture that
increase the power of experimental data. We propose a systems pharmacology workﬂow for the reﬁnement of data and the
generation of future therapeutic hypotheses.
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Introduction
The expansion of available genomic and proteomic data has
enhanced our understanding of biomolecular interaction
networks. Consequently, the development of systems biology
approaches has enabled us to better understand how cellular
behaviour emerges from these networks (Boran and Iyengar,
2010a). Systems-level approaches have been used to predict
the on- and off-target impacts of an intervention (Boran and
Iyengar, 2010b) and to identify the most sensitive compo-
nents in pathways that suggest candidate drug targets
(Benson et al., 2013). They also have the untapped potential
to suggest therapies comprising combinations of drugs
chosen to strategically reprogram biomolecular interaction
networks in order to drive the system from a diseased to a
healthy state (Zhao et al., 2013; van Hasselt and van der
Graaf, 2015; Watterson and Ghazal, 2010). This approach,
known as systems pharmacology (Boran and Iyengar, 2010b;
Westerhoff et al., 2015), is underpinned by the expansion in
pathway, pharmacology and medicinal chemistry databases.
For example, WikiPathways held 804 human pathways
(http://www.wikipathways.org/index.php/WikiPathways:
Statistics) with 253 added in 2015 (Kutmon et al., 2016).
Kyoto Encyclopedia of Genes and Genomes (KEGG) PATHWAY
holds 518 pathway maps (Kanehisa et al., 2017) (http://www.
kegg.jp/kegg/docs/statistics.html). Reactome currently holds
2148 human pathways involving 10684 proteins and isoforms
(http://reactome.org/stats.html) (Croft et al., 2014; Fabregat
et al., 2016). ChEMBL version 23 (Gaulton et al., 2016) includes
14675320 bioactivities, and the International Union of Basic
and Clinical Pharmacology/British Pharmacological Society
(IUPHAR/BPS) Guide to Pharmacology (GtoPdb) contains
15281 curated interactions in its 2017.5 release (Southan et al.,
2016). In 2016, the Food and Drug Administration (FDA) new
drug approvals fell to 22, following 45 approvals in 2015 (US
Food and Drug Administration, 2016a; US Food and Drug
Administration, 2016bb). According to DrugBank release 5.0,
their distinctmolecular count of approved small-molecule drugs
is 2037 (Law et al., 2013).
As this catalogue of pharmacological interactions grows
and our understanding of pathway systems expands, it will
be advantageous to integrate these resources in order to de-
vise new potential therapies. Drug combination-based inter-
ventions represent an opportunity for therapy development
that can yield one-size-ﬁts-all or personalized/stratiﬁed thera-
pies, and they can target pathways precisely rather than
perturbing entire networks. Two US National Institute for
Health workshop white papers have made a strong case for
systems pharmacology (Sorger et al., 2011) as a way to reduce
attrition in therapy, to stimulate drug development, to bridge
the gap between network biology and translational medicine
and to enhance industrial–academic collaborations. Systems
pharmacology is also likely to impact upon genomic
medicine (Westerhoff et al., 2015), Systems Pathology, Sys-
tems Biology and Pharmacometrics (van der Greef and
McBurney, 2005; Vicini and van der Graaf, 2013) and the
tools that could contribute to systems pharmacology have
been described (Lehár et al., 2007; Berger and Iyengar, 2009;
Kell and Goodacre, 2014).
Previous work under the domain of systems pharmacology
has primarily focussed on pharmacokinetic–pharmacodynamic
modelling (Darwich et al., 2017). Industry has evaluated systems
pharmacology as a tool to inform trial design in areas of
cardiovascular disease, endocrinology, neurogenerative disease,
respiratory disease, oncology and infectious disease (Visser et al.,
2014) and to inform regulatory development (Visser et al., 2014;
Peterson andRiggs, 2015). There have a been a number of speciﬁc
studies of nerve growth factor (Benson et al., 2013), coagulation
(Wajima et al., 2009), innate immunity (Madrasi et al., 2014), can-
cer (Abaan et al., 2013) and atherosclerosis (Pichardo–Almarza
et al., 2015).
However, whilst there is much enthusiasm for systems
pharmacology as a tool to improve the efﬁcacy and safety of
the drug development pipeline (van der Graaf and Benson,
2011; Rostami-Hodjegan, 2012; Trame et al., 2016), the prac-
tical challenges of systematically amalgamating pharmacol-
ogy and pathway biology in a coherent framework have not
been adequately addressed.
Here, we describe a systems pharmacology study of the
cholesterol biosynthesis pathway, detailing the barriers to
progress that we encountered and suggesting solutions to
these impediments, before proposing amodel of how systems
pharmacology studies could be conducted in future. In par-
ticular, we build a dynamic ordinary differential equation
(ODE) model of the pathway, which we parameterize as far
as possible from the literature. We identify relevant pharma-
cological agents that act on this pathway and parameterize
them as far as possible from the literature and online data-
bases. We then use computational optimization techniques
to identify the drug combinations that are most effective at
suppressing the outputs of the pathway that lead to choles-
terol production and that minimize off-target effects. In com-
pleting our analysis, we identify many of the problems that
prevent this type of work being undertaken routinely, and
we suggest solutions that would enable systems pharmacol-
ogy to make a regular contribution to therapy development.
As explored in previous studies (Mazein et al., 2011; 2013;
Watterson et al., 2013; Bhattacharya et al., 2014; Caspi et al.,
2016), the cholesterol biosynthesis pathway is critical to both
cardiovascular health (Lewington et al., 2007; Henderson
et al., 2016; Parton et al., 2016) and innate immunity (Blanc
et al., 2011; Lu et al., 2015; Robertson et al., 2016). As the tar-
get of the statin class of drug, we would expect this pathway
to be amongst the most thoroughly characterized, and for
this reason, we have chosen it for our feasibility study of sys-
tems pharmacology. For simplicity, we have focused on the
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segment of the pathway that transforms acetyl-CoA to
squalene and that forks to produce geranylgeranyl-di-
phosphate. As a precursor to cholesterol, we would expect
squalene synthesis to track cholesterol synthesis and so we
use this as a proxy. The branch of the pathway that produces
geranylgeranyl-diphosphate has been shown tomediate both
the innate immune response (Blanc et al., 2011) and the
myopathy side-effects associated with statin treatment
(Wagner et al., 2011). Any intervention that demonstrates a
minimal impact on this branch will avoid one of the
signiﬁcant side effects associated with standard cholesterol
lowering treatments.
Methods
Pathway production
We started from the representations available in KEGG
(Kanehisa et al., 2014), MetaCyc (Caspi et al., 2016) and the
GtoPdb (Southan et al., 2016) taking these resources to be
representative of the community of online pathway data-
bases. We reviewed the primary literature to establish the
structure of the mevalonate portion of the cholesterol
biosynthesis pathway, in particular the enzymes involved
in the pathway, the reactions they catalyse, their subcellular
localization, the species in which they were identiﬁed and
any known isoforms.
Diagrams of the pathway were created using the Systems
Biology Graphical Notation (SBGN) (Le Novère et al., 2009),
the yEd diagram software (yWorks GmbH, http://www.
yworks.com/products/yed) and the SBGN-ED add-on to
VANTED (Czauderna et al., 2010). From these diagrams, we
built kinetic models as systems of ODEs.
The ODE model of this pathway was built using
Michaelis–Menten kinetics to describe each step except the
interactions consuming isopentenyl diphosphate and
producing geranylgeranyl diphosphate and pre-squalene
diphosphate. These steps were described using mass action
kinetics in order to simplify the process of calculating the
steady state of the model and hence the steady state behav-
iour of the pathway. Mass action kinetics were justiﬁed by
the expectation that the pathway interactions would operate
far from substrate saturation making the dynamics robust
against small ﬂuctuations in enzyme concentration. Mass ac-
tion rate constants were calculated from the Kcat, Km and Ki
parameters as described elsewhere (Watterson et al., 2013)
and enzyme concentrations were taken from experimentally
measured values (Watterson et al., 2013).
The pathway map and the associated mathematical
model are available from the Supporting Information Files
S1 and S2 as Systems Biology Graphical Notation Markup
Language (SBGN-ML) (Van Iersel et al., 2012) and Systems
Biology Markup Language (SBML) ﬁles (Hucka et al., 2003)
respectively.
Pathway parameterization
We identiﬁed the kinetic parameters that quantify each reac-
tion unambiguously (Km and Kcat) using the Braunschweig
Enzyme Database (BRENDA) (Chang et al., 2015) and veriﬁed
the values described against those in the primary literature. In
many instances, enzymes were associated with multiple
kinetic parameter sets. We selected kinetic parameters based
upon the following criteria: (i) speciﬁcity to the wild-type
enzyme in one of the three main mammalian model species:
human, mouse or rat; (ii) sourced from a primary literature
reference describing in vivo or in vitro experimental data as
opposed to computationally derived structural modelling
data; and (iii) sourced from a reference that could be accessed
and therefore veriﬁed. For many enzymes, this yielded a
range of values for each parameter, and where this was the
case, we used the mean of the values obtained.
Inhibitor list
Inhibitor compounds not already indexed in GtoPdb were
identiﬁed for each reaction from ChEMBL and BRENDA,
databases that we took to be representative of the commu-
nity of target databases. We included a compound in our
set if it met three criteria: (i) the enzyme used in the assay
was wild-type from one of the three main mammalian
model species: human, mouse or rat; (ii) an experimentally
determined reaction-speciﬁc inhibition constant (Ki) was
reported; and (iii) the assay conditions were reported.
Crucially, all data were checked against the primary litera-
ture references. Where this yielded a range of inhibition
constants for nominally identical compounds, the most
potent Ki values were used.
We veriﬁed the correct chemical structures of the inhibi-
tors by cross-referencing the original references against the
online chemical databases PubChem (Kim et al., 2016) and
ChemSpider (Pence andWilliams, 2010). The actual chemical
structures of the marketed statin drugs were established by
checking the FDA labels and the international non-
proprietary name-assigned structures on the World Health
Organization MedNet site (https://mednet-communities.
net/inn). Comparison of unique structural identiﬁers allowed
us to identify duplicates within the ChEMBL, BRENDA and
literature-derived dataset, and to establish whether the chem-
ical structure reported in a given reference matched the
marketed drug or research compound structures.
Curated content describing the enzymes in this pathway,
their substrates and small molecule inhibitors was used to
consolidate and expand GtoPdb using the same approach
and guidelines as described elsewhere (Pawson et al., 2014).
The enzymes, list of inhibitors and kinetic parameters are
now all updated in the July 2016.3 release of GtoPdb.
Hypothesis generation
We combined ODE kinetic models, the pathway parameters
and the inhibitor parameters to create a model describing
the dynamics of the mevalonate pathway. We sought to
identify the drug combination that would best suppress
the production of squalene as a precursor for cholesterol,
but would also maintain production of geranylgeranyl-
diphosphate at the same levels as in the absence of any in-
hibitors, thereby eliminating a signiﬁcant side-effect of
treatment. Firstly, we identiﬁed the steady-state activity of
the pathway in the absence of any inhibitors. Then we used
computational optimization to identify the drug combina-
tion that, at steady state, minimized squalene production,
but left geranylgeranyl diphosphate production the same
as in the absence of inhibitors.
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This was implemented using the Genetic Algorithm func-
tion available on Matlab (MathWorks, http://www.
mathworks.com) in parallel with a population size of 200
and a function tolerance of 106. Matlab was chosen as the
modelling platform for its ﬂexibility, stability and compre-
hensive libraries. The genetic algorithm started with one in-
stance of a set of drug concentrations where each drug was
assigned a concentration equal to its Ki. A 199 further in-
stances of sets of drug concentrations were automatically
generated from this instance by adding Gaussian noise to
the concentration of each drug (with standard deviation 1,
the default setting). These 200 instances comprised the ﬁrst
generation of candidate interventions. All instances of sets
of concentrations were evaluated for their efﬁcacy at sup-
pressing squalene synthesis whilst maintaining geranylger-
anyl diphosphate production. Two hundred new instances
were created as a second generation of candidate interven-
tions from the two most effective instances of the ﬁrst gener-
ation and with the addition of Gaussian noise. The 200 new
instances were then themselves evaluated with the two most
effective instances used to generate a further 200 new in-
stances, the third generation. This process was repeated until
we arrived at instances from which no improvement in efﬁ-
cacy could be found for 20 consecutive generations, at which
point we interpreted the best performing instance identiﬁed
thus far as optimal.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharma-
cology.org, the common portal for data from the
IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al.,
2016), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2015/16 (Alexander et al., 2015).
Results
Pathway production
We produced the model of the mevalonate arm of the choles-
terol biosynthesis pathway shown in Figure 1 in SBGN nota-
tion, describing the sequence of metabolic steps that lead
from acetyl-CoA and acetoacetyl-CoA consumption to
squalene and geranylgeranyl diphosphate production. This
pathway comprises 12 steps (see Table 1), involving 10 en-
zymes and 14 metabolites.
The parameters required for the resulting ODE model are
shown in Table 1. After pooling results across mouse, human
and rat models, we were able to obtain experimental values
for only 12 out of the 24 required parameters. Across the stud-
ies reported, pH values ranged from 7.0 to 8.0 and tempera-
tures ranged from 25°C to 37°C, although in some studies,
neither pH nor temperature values were given. When veriﬁed
against the primary references, we found that one parameter
value obtained from BRENDA was missing from the literature
reference provided, suggesting that it had been misattributed
[Kcat = 0.023/s for hydroxymethylglutaryl-Coa reduc-
tase (HMGCR)]. A second parameter had been transcribed
(for diphosphomevalonate decarboxylase) where the
literature source contradicted itself, specifying Km = 10 μM
in the abstract and Km = 10 mM in the manuscript. Because
computational hypothesis generation is highly sensitive to
the values of the parameters, ambiguous or inaccurate
reporting can have a signiﬁcant impact on any predictions
made.
Substrates were reported in varying levels of structural de-
tail. Common names were used that could refer to multiple
explicit forms of a chemical structure. However, variations
in the chirality and chemical structure can signiﬁcantly affect
substrate afﬁnity. The relative enzyme concentrations had
been inferred previously (Watterson et al., 2013) and are
listed in Table 2.
Figure 1
The mevalonate arm of the cholesterol biosynthesis pathway.
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Supporting Information Table S1 compares representa-
tions of the cholesterol biosynthesis pathway across themain
publicly available pathway and chemical databases. It
includes a summary of cross-referencing between databases
with standard identiﬁers for unambiguous representation,
which will be essential for future cross-platform
interoperability.
Inhibitors
The inhibitors obtained from GtoPdb, BRENDA and the
literature, together with their inhibition constants (Ki), are
listed in Table 3. Six of the 10 enzyme targets had quantiﬁed
parameters in humans. It was necessary to include two inhib-
itors that had been only reported for rat enzymes [L-659,699
for hydroxymethylglutaryl-CoA synthase (HMGCS1)
and 3-hydroxy-3-methyl-6-phosphohexanoic acid for
phosphomevalonate kinase] in order to maximize
coverage of the pathway. Two enzyme paralogues
(isopentenyl diphosphate Δ-isomerases 1 and 2) had
no reported inhibitors with available Ki values, representing
a region of the pathway that cannot currently be modulated
in our modelling process. This can be contrasted with the
enzymes HMGCR and farnesyl diphosphate synthase,
each of which had an extensive list of inhibitors. Inhibition
constants could be obtained for 8 of the 10 enzymes in the
pathway. Where reported, these values came from studies
conducted across a range of pH levels from 6.8 to 7.5 and
temperatures from 25°C to 37°C.
Both explicit structure and name-to-structure (n2s)
ambiguities existed around the reporting of inhibitor enti-
ties. In some cases, the common or trade name of a com-
pound was used, without speciﬁcation of the exact
chemical structure and stereochemistry. In other cases, we
found a different n2s assignment across different database
resources or indeed within the same resource. For example,
under the HMGCS1 entry of BRENDA, the same inhibitor
is listed twice as L-659,699 and (E,E)-11-[3-(hydroxy-
methyl)-4-oxo-2-oxytanyl]-3,5,7-trimethyl-2,4-
undecadienenoic acid.
Several results recorded in ChEMBL were transcribed
against the incorrect drug target. Three inhibitors listed
against the enzyme HMGCS1 describe results obtained from
experiments with HMGCR (Balasubramanian et al., 1989).
There were also cases where the incorrect species had been re-
corded. For example, the compound with ChEMBL ID
CHEMBL88601 cited in one study (Procopiou et al., 1994)
(ChEMBL document ID CHEMBL1151052) is listed against
the human squalene synthase (FDFT1) enzyme, whilst in
fact, the paper describes results for the yeast Candida albicans
and rats.
Hypothesis generation
In order to complete the gaps in the available parameter sets,
we proceeded by assuming that where parameters were taken
from separate studies, the same metabolite chemical
structures were referenced. For all the unknown parameters,
we substituted a single representative value, obtained by
averaging across all known corresponding parameters.
Calculating the steady-state behaviour of the pathway in
the absence of inhibitors yielded the proﬁle of ﬂux shown
on the left of Figure 2A, which we take to be wild-type
behaviour. Using computational optimization, we identiﬁed
the following drug combination that produced the steady-
state proﬁle of ﬂux shown in the middle of Figure 2A and in
Figure 2B: L-659,699 = 0.0294 nM, rosuvastatin = 2.60 nM,
farnesyl thiodiphosphate = 0.0340 nM, cinnamic
acid = 0.00104 nM, 6-ﬂuoromevalonate 5-
diphosphate = 0.0213 nM, zoledronic acid = 9.97 nM,
BPH-628 = 5.86 nM; zaragozic acid A = 0.755 nM (see
Table 3 and Supporting Information Tables S2 and S3). Here,
the production of squalene, a precursor of cholesterol, is
heavily suppressed and the production of geranylgeranyl
diphosphate is maintained at wild-type levels. In Figure 2B,
we see speciﬁcally the ﬂux at endpoints of the two pathway
branches. With this drug combination, the ﬂux from
geranylgeranyl diphosphate → protein prenylation is the
same between the wild-type (inhibitor free) case and the
optimal multi-drug intervention case. However, the ﬂux from
squalene → cholesterol synthesis has been signiﬁcantly
suppressed.
In Figure 2A, B, we compare the ﬂux proﬁles for wild-
type and optimal multi-drug interventions to the case
where rosuvastatin, a type of statin, is applied alone. This
inhibitor targets the interaction catalysed by HMGCR, and
we chose a concentration sufﬁcient to suppress the rate of
squalene formation and consumption to the same extent
as the multi-drug intervention. As can be seen in Figure 2
B, rosuvastatin intervention impacts upon both branches
of the pathway, suppressing geranylgeranyl diphosphate
formation and protein prenylation as an off-target effect
of treatment.
Interestingly, a concentration of 362 nM rosuvastatin was
required to achieve the same level of squalene suppression as
the multi-drug intervention. The greatest individual drug
concentration required in the optimal multi-drug interven-
tion was 9.97 nM, and the total combined concentration
was 19.3 nM, a dramatically lower dosage.
The value of drug combinations can also be seen in
Supporting Information Figure S1 where we consider the im-
pact of pairs of drugs (Lehár et al., 2007). Here, we see that
drug pairs with targets above the fork inhibit the ﬂux through
both pathway endpoints (Supporting Information Figure
S1A, B). Drug pairs with targets above and below the fork
together inhibit the ﬂux through the cholesterol synthesiz-
ing branch (Supporting Information Figure S1C, D). How-
ever, drug pairs with targets above and below the fork at
high doses can have a low impact on the ﬂux through the
protein prenylation branch (Supporting Information Figure
S1E, F). Critically, Supporting Information Figure S1B, E
shows that concentrations can be selected that signiﬁcantly
suppress the cholesterol synthesizing branch but that do
not suppress the protein prenylation branch. The results
demonstrate comparable impact to the multi-drug interven-
tion described above, but at higher individual and combined
concentrations.
In order to identify the optimal multi-drug combination,
it was necessary to use a high-performance computing
(HPC) platform. However, the HPC demands were modest.
Using an eight-node desktop computer running MATLAB in
parallel, we can see that the score (a dimensionless value,
greater than or equal to zero, that quantiﬁes how effectively
the best performing multi-drug intervention identiﬁed
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Table 1
A list of the enzymes of the mevalonate branch of the cholesterol synthesis pathway, with gene and protein identiﬁers and EC numbers
E.C
number
Enzyme/
GtoPdb
target ID
UniProt
ID
HGNC
ID
IUBMB
enzyme
approved name
Reaction
catalysed
Km(mM)/
PMID
Reported
substrate/
GtoPdb ligand ID
Kcat
(s-1)/
PMID
2.3.3.10 HMGCS1/
638
Q01581 5007 Hydroxymethylglutaryl-
CoA synthase
Acetyl CoA + H2O
+ acetoacetyl
CoA = (S)-3-
hydroxy-3-
methylglutaryl-
CoA +
coenzyme A
0.009/
6118268
Acetyl-
CoA/3038
–
– – – – – 0.2/6118268 Acetyl-
CoA/3038
–
– – – – – 0.073/
19706283
Acetyl-
CoA/3038
–
– – – – – 0.076/
19706283
Acetyl-
CoA/3038
–
– – – – – 0.084/
19706283
Acetyl-
CoA/3038
–
– – – – – 0.029/
7913309
Acetyl-
CoA/3038
–
1.1.1.34 HMGCR/
639
P04035 5006 Hydroxymethylglutaryl-
CoA reductase
(NAPDH)
(S)-3-Hydroxy-
3-methylglutaryl-
CoA + 2 NADPH =
mevaldyl CoA
+ 2NADP+
0.006/
4985697
3-Hydroxy-3-
methylglutaryl-
CoA/3040
–
– – – – – 0.012/
4985697
3-Hydroxy-3-
methylglutaryl-
CoA/3040
–
– – – – Mevaldyl CoA
+ 2NADP+ = (R)-
mevalonate +
coenzyme
A + 2 NADP+
0.01/
10392455
3-Hydroxy-3-
methylglutaryl-
CoA/3040
–
– – – – – 0.014/
10392455
3-Hydroxy-3-
methylglutaryl-
CoA/3040
–
– – – – – 0.015/
10392455
3-Hydroxy-
3-methylglutaryl-
CoA/3040
–
– – – – – 0.019/
10392455
3-Hydroxy-3-
methylglutaryl-
CoA/3040
–
– – – – – 0.024/
10392455
3-Hydroxy-
3-methylglutaryl-
CoA/3040
–
– – – – – 0.07/
16128575
3-Hydroxy-
3-methylglutaryl-
CoA/3040
–
– – – – – 0.6/ 3-Hydroxy-
3-methylglutaryl-
CoA/3040
–
– – – – – 0.068/
18446881
Hydroxymeth
ylglutaryl-CoA
0.023/
18446881
– – – – – 0.004/
7077140
S-3-Hydroxy-
3-methylglutaryl-
CoA/3040
–
continues
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Table 1
(Continued)
E.C
number
Reaction
catalysed Organism
Reported
conditions
Mean
Km
(mM)
Substituted
mean
Km
Substituted
mean
Kcat
2.3.3.10 Acetyl CoA + H2O
+ acetoacetyl
CoA = (S)-3-hydroxy-3-
methylglutaryl-CoA +
coenzyme A
Rattus
norvegicus
absence of
acetoacetyl-
CoA, hydrolysis
reaction
0.0785 – 6.651575
– Rattus
norvegicus
0.01 M
acetoacetyl-
CoA
– – –
– Homo
sapiens
– – – –
– Homo
sapiens
– – – –
– Homo
sapiens
– – – –
– Homo sapiens – – – –
1.1.1.34 (S)-3-Hydroxy-
3-methylglutaryl-
CoA + 2 NADPH =
mevaldyl CoA
+ 2NADP+
Rattus
norvegicus
Only one
enantiomer
0.0765 – 0.0023
– Rattus norvegicus – – – –
Mevaldyl CoA
+ 2NADP+ = (R)-
mevalonate +
coenzyme
A + 2 NADP+
Mus musculus Enzyme from
tumour
– – –
– Mus musculus Enzyme from liver
and tumour
– – –
– Mus musculus Enzyme from liver,
implanted tumour
– – –
– Mus musculus Enzyme from liver,
implanted tumour
– – –
– Mus musculus Enzyme
from liver
– – –
– Homo sapiens – – – –
– Homo sapiens pH 7.5/Temp
not speciﬁed
– – –
– Rattus norvegicus – – – –
– Rattus norvegicus – – – –
2.7.1.36 ATP + (R)
-mevalonate
= ADP +
(R)-5-
phosphomevalonate
Rattus
norvegicus
pH 7.5/25C 0.0337 – –
– Rattus
norvegicus
pH 7.5/34C – – –
– Homo sapiens pH 7.5/30C – – –
– Homo sapiens pH 7.0/30C – – –
2.7.4.2 ATP + (R)-5-
phosphomevalonate =
Homo
sapiens
pH 7.0/30C 0.034 – 6.651575
continues
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Table 1 (Continued)
E.C
number
Enzyme/
GtoPdb
target ID
UniProt
ID
HGNC
ID
IUBMB
enzyme
approved name
Reaction
catalysed
Km(mM)/
PMID
Reported
substrate/
GtoPdb ligand ID
Kcat
(s-1)/
PMID
2.7.1.36 MVK/640 Q03426 7530 Mevalonate
kinase
ATP + (R)
-mevalonate
= ADP +
(R)-5-
phosphomevalonate
0.035/
14680942
(RS)-mevalonate/
3056
–
– – – – – 0.035/
17964869
(RS)-mevalonate/
3056
21.9/
18302342
– – – – – 0.0408/
18302342
(RS)-mevalonate/
3056
–
– – – – – 0.024/
9325256
Mevalonate/
3056
–
2.7.4.2 PMVK/641 Q15126 9141 Phosphomevalonate
kinase
ATP + (R)-5-
phosphomevalonate =
ADP + (R)-5-
diphosphomevalonate
0.034/
17902708
(R)-5-
Phosphomevalonate/
3046
–
4.1.1.33 MVD/642 P53602 7529 Diphosphomevalonate
decarboxylase
ATP + (R)-5-
diphosphomevalonate =
ADP + phosphate
+ isopentenyl
diphosphate + CO2
0.02/
8744421
5-
Diphosphomevalonate/
3055
–
– – – – – 0.0289/
18823933
5-
Diphosphomevalonate/
3055
4.5/
18823933
– – – – – 0.036/
16626865
5-
Diphosphomevalonate/
3055
–
– – – – – 0.036/
17888661
5-
Diphosphomevalonate/
3055
–
– – – – – 0.01/
11913522
Mevalonate
diphosphate/
3055
–
5.3.3.2 IDI1 and
IDI2*/646
& 647
Q13907/
Q9BXS1
5387/
23487
Isopentenyl-
diphosphate
delta isomerase
Isopentenyl
diphosphate =
dimethylallyl
diphosphate
0.0228/
17202134
Isopentenyl
diphosphate/3048
–
– – – – – 0.033/
8806705
Isopentenyl
diphosphate/3048
–
2.5.1.1 FDPS/644 P14324 3631 Farnesyl
diphosphate
synthase
Dimethylallyl
diphosphate +
isopentenyl
diphosphate
= diphosphate +
geranyl diphosphate
– – –
2.5.1.10 – – – – Geranyl diphosphate
+ isopentenyl
diphosphate =
diphosphate +
trans,trans-
farnesyl
diphosphate
– – –
2.5.1.1 GGPS1/643 O95749 4249 Farnesyltranstransferase Dimethylallyl
diphosphate +
isopentenyl
diphosphate
= diphosphate
+ geranyl
diphosphate
– – –
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Table 1 (Continued)
E.C
number
Reaction
catalysed Organism
Reported
conditions
Mean
Km
(mM)
Substituted
mean
Km
Substituted
mean
Kcat
ADP + (R)-5-
diphosphomevalonate
4.1.1.33 ATP + (R)-5-
diphosphomevalonate =
ADP + phosphate
+ isopentenyl
diphosphate + CO2
Rattus norvegicus – 0.0262 – –
– Homo sapiens 30C – – –
– Rattus norvegicus – – – –
– Rattus norvegicus – – – –
– Mus musculus pH 7.2 – – –
5.3.3.2 Isopentenyl
diphosphate =
dimethylallyl
diphosphate
Homo sapiens pH 8.0 0.0279 – 6.651575
– Homo sapiens – – – –
2.5.1.1 Dimethylallyl
diphosphate +
isopentenyl
diphosphate
= diphosphate +
geranyl diphosphate
– – – 0.0351375 6.651575
2.5.1.10 Geranyl diphosphate
+ isopentenyl
diphosphate =
diphosphate +
trans,trans-
farnesyl
diphosphate
– – – 0.0351375 6.651575
2.5.1.29 Trans,trans-
farnesyl
diphosphate +
isopentenyl
diphosphate =
diphosphate +
geranylgeranyl
diphosphate
Rattus norvegicus pH 7.0/37C 0.0027 – –
– Homo sapiens pH 7.7/37C – – –
– Rattus norvegicus pH 7.0/37C – – –
– Homo sapiens pH 7.7/37C – – –
2.5.1.21 2 Trans,trans-
farnesyl
diphosphate =
diphosphate +
presqualene
diphosphate
Homo sapiens – 0.0016 – 6.651575
Presqualene
diphosphate
+ NAD(P)H + H+
= trans-squalene +
diphosphate
+ NAD(P)+
Rattus norvegicus – – – –
BJP H Benson et al.
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achieves our objective, with zero indicating success)
converges rapidly on an effective drug combination. It
successfully identiﬁed an optimal combination in 46 min
and achieved an approximately optimal solution in less than
10 min.
The results of our curation of the pathway and the inhib-
itors that target it are available in GtoPdb at http://www.
guidetopharmacology.org/GRAC/FamilyDisplayForward?
familyId=104, an example of which is shown in Supporting
Information Figure S2.
The model produced is available from http://biomodels.
org (Chelliah et al., 2013) (ID: MODEL1506220000).
Discussion
The importance of systems pharmacology
Multi-drug interventions. Multi-drug approaches are already
employed in areas including HIV and oncology (Petrelli and
Giordano, 2008; Thakur and Marchand, 2012). However, the
existing interventions have typically been developed
heuristically, rather than through systematic studies of the
pathways involved, requiring signiﬁcant domain expertise and
subjective judgement. Systems pharmacology introduces
objective metrics that have the potential to transform therapy
Table 1 (Continued)
E.C
number
Enzyme/
GtoPdb
target ID
UniProt
ID
HGNC
ID
IUBMB
enzyme
approved name
Reaction
catalysed
Km(mM)/
PMID
Reported
substrate/
GtoPdb ligand ID
Kcat
(s-1)/
PMID
2.5.1.10 – – – – Geranyl diphosphate
+ isopentenyl
diphosphate =
diphosphate +
trans,trans-
farnesyl
diphosphate
– – –
2.5.1.29 – – – – Trans,trans-
farnesyl
diphosphate +
isopentenyl
diphosphate =
diphosphate +
geranylgeranyl
diphosphate
0.0029/
17846065
Isopentenyl
diphosphate/
3048
–
– – – – – 0.003/
16698791
Isopentenyl
diphosphate/
3048
–
– – – – – 0.00071/
17846065
Trans,trans-
farnesyl
diphosphate/
3050
–
– – – – – 0.0042/
16698791
Trans,trans-
farnesyl
diphosphate/
3050
0.204/
16698791
2.5.1.21 FDFT1/645 P37268 3629 Farnesyl-
diphosphate
farnesyl
transferase 1
2 Trans,trans-
farnesyl
diphosphate =
diphosphate +
presqualene
diphosphate
0.0023/
9473303
Farnesyl
diphosphate/
2910
–
– – – – Presqualene
diphosphate
+ NAD(P)H + H+
= trans-squalene +
diphosphate
+ NAD(P)+
0.001/
1569107
Trans-farnesyl
diphosphate/
3050
–
Reported substrates, kinetic values and details of the experimental studies from which they were obtained, along with references are recorded.
Please note that ligands outlined in the table are listed using the nomenclature from the original literature. Where the reference did not specify the
isomer used experimentally, it was assumed the racemate was used.
FDPS, farnesyl diphosphate synthase; IDI1, isopentenyl diphosphate delta isomerase 1; IDI2, isopentenyl diphosphate delta isomerase 2; MVD,
diphosphomevalonate decarboxylase; MVK, mevalonate kinase; PMVK, phosphomevalonate kinase.
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development, yielding therapeutichypothesesmore rapidly and
cost-effectively.
Many diseases are multifactorial in nature, involving
multiple pathways in their pathology. Effective future
therapies will likely employ multi-drug approaches that
targetmultiple points in the network of pathways responsible
(i.e. polypharmacology). Promiscuous drugs can be
incorporated advantageously into the generation of these
hypothetical interventions, provided that their interactions
are known and parameterized.
Multi-drug approaches can minimize the pleotropic
effects of an intervention. As we demonstrated for statins,
where a single drug intervention suppressed the output of a
pathway to the same extent as multiple drugs targeting the
same pathway, not only was the dose of each of the multiple
drugs signiﬁcantly lower than the dose of the single drug
but also the combined dose of all of the multiple drugs was
signiﬁcantly lower than the dose of the single drug. This
intrinsically reduces the risk from off-target or pleotropic
effects for each drug.
The systems pharmacology approach allows us to pre-
dict multi-drug strategies that may be optimal to treat a
disease and can be used as a prioritization triage for future
drug development. It can support personalized and strati-
ﬁed medicine, where we adapt the parameter sets of the
underlying models of pathway activity to represent an in-
dividual (for personalized medicine) or a subpopulation
(for stratiﬁed medicine) and we develop interventions that
are customized to be optimal for the patient or patient
group. A challenge lies in developing optimized therapies
so that they preferentially target key tissues. Pathway
models and pharmacological interactions can be made
tissue speciﬁc by generating a new parameter set for each
tissue. Hypothesis generation would then use optimization
to determine an intervention that impacted upon a key
pathway in a key tissue, leaving other pathways unchanged
across all tissues and with a minimal impact on the key
pathway in non-targeted tissues.
Drug development. Fewmulti-drug treatmentsmake it through
the development process. The number of combinational
therapies listed in the Therapeutic Target Database at the time
of writing is 115 (Qin et al., 2014). A combination therapy,
LCZ696, with the brand name Entresto, was approved in 2015
and is in Phase III of clinical trials for the treatment of
cardiovascular disorders. Establishing drug combinations using
a conventional drug development pipeline creates signiﬁcant
challenges as development essentially replicates the single drug
development process multiple times. Systems pharmacology is
therefore critical to expanding the range of multi-drug
interventions available in a cost-effective manner. Although it
may add extra steps to the preclinical stages of the drug
development process, it could have a signiﬁcant positive
impact on the cost-efﬁciency associated with each success by
reducing the attrition rate in the later stages of the pipeline
(Bowes et al., 2012).
Integrating our understanding of pharmacology and sys-
tems biology will also enable us to make better predictions
of the behaviour of individual drugs. For example, squalene
synthase (FDFT1) has been investigated as a potential drug
target that lies downstream of HMGCR, the target for statins,
in the cholesterol biosynthesis pathway (see Figure 1). FDFT1
catalyses an interaction after the fork to geranylgeranyl-
diphosphate production, and it has been speculated that
squalene synthase inhibitors might suppress cholesterol
production without impacting on the geranylgeranyl-
diphosphate producing branch, in contrast to statin treat-
ment. However, squalene synthase inhibitors typically have
Ki values orders of magnitude greater than the typical Ki for
statins (See Table 3). As a result, squalene synthase inhibitor
concentrations are required to be orders of magnitude greater
than statin concentrations to suppress the corresponding
enzyme activity comparably. Such high concentrations risk
unforeseen off-target effects, making squalene synthase
inhibitors a higher risk drug to develop.
Systems level analysis. At the heart of systems pharmacology
is the growing recognition that we will only be able to truly
understand the best ways to therapeutically intervene in
physiological function by considering biology at a systems
level. The network of interactions that mediate
physiological function is a dynamical system, and just as
health and disease are different dynamical states of cells,
tissues and organs, they also describe different dynamical
states of the networks (Ahn et al., 2006). In a network
context, dynamical states can comprise a single stable
conﬁguration of the whole network or a sequence of
conﬁgurations that repeat cyclically and stably. However, it
is the conﬁguration (species concentrations, distributions
and structural conformations) of the network as a whole, or
at least of critical subnetworks, that relate to phenotype,
rather than any single component of the network (Lewis
and Glass, 1991).
Small networks often yield dynamics that are intuitive
and predictable. However, as networks become larger and
richer in structure, novel and often counter-intuitive
dynamics can emerge and it will only be once we are able
to build high-conﬁdence models at this scale that the full
potential of systems level studies will be realized (Aderem,
2005). Building high conﬁdence networks at this scale is
Table 2
Normalized enzyme levels
Enzyme Level
HMGCS1 1441
HMGCR 258
MVK 76
PMVK 874
MVD 111
IDI1 2707
IDI2 –
FDPS 7029
GGPS1 86
FDFT1 3425
FDPS, farnesyl diphosphate synthase; IDI1, isopentenyl diphosphate
delta isomerase 1; IDI2, isopentenyl diphosphate delta isomerase 2;
MVD, diphosphomevalonate decarboxylase; MVK, mevalonate ki-
nase; PMVK, phosphomevalonate kinase.
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inherently challenging as we see here. Coherently and
unambiguously parameterizing all the interactions of a
network is a signiﬁcant logistical challenge. However, we
have also seen that doing so enables us to identify and
address the side-effects of treatment whilst the therapy is
being designed, rather than retroactively. Hence, systems-
level approaches are well suited to pharmacological
applications.
Current impediments to systems pharmacology
Problem 1: lack of systematic recording
The absence of systematic and rigorous descriptions of me-
tabolites and pharmaceutical compounds poses a signiﬁcant
challenge. Example 1, ﬂuvastatin consists of two
enantiomers, represented by PubChem compound identiﬁers
(CIDs) 1548972 and 446155, with the 3R, 5S enantiomer
(CID 446155) being signiﬁcantly more pharmacologically ac-
tive than the other (Di Pietro et al., 2006; Boralli et al., 2009).
Commercial preparations used in vitro often vary in their
stereochemical composition, with both enantiomers
available individually, as well as in a racemic mixture. How-
ever, the authors did not always specify the stereochemical
composition used despite this necessarily impacting upon
the inhibition constant, Ki, reported. Example 2, mevalonate
is a metabolite that occurs naturally in mammals as the (R)-
isomer form. Sigma-Aldrich currently refers to its marketed
version as ‘(RS)-mevalonic acid’. However, in one study
(Potter and Miziorko, 1997), the metabolite is obtained from
the supplier Sigma-Aldrich, and it is recorded on BRENDA
Figure 2
(A) The proﬁle of ﬂux through the pathway shown in Figure 1 described as a cone plot for the three scenarios: wild-type (treatment free), opti-
mized multi-drug intervention and single-drug statin-like intervention. Cone size and colour both represent ﬂux level. We show only the ﬂux lead-
ing to cholesterol synthesis [the ﬂux to protein prenylation is presented in (B)]. Interactions are numbered by their product: (1: 3-hydroxy-3-
methylglutaryl-CoA; 2: melvaldyl-CoA, 3: mevalonate, 4: mevalonate-P, 5: mevalonate diphosphate, 6: isopentenyl diphosphate, 7: dimethylallyl
diphosphate, 8: geranyl diphosphate, 9: farnesyl diphosphate, 10: presqualene diphosphate, 11: squalene, 12: cholesterol synthesis). (B) The ﬂux
through the endpoints of the two branches for the three scenarios: wild-type, optimized multi-drug intervention and single-drug statin-like
intervention. Flux through the squalene/cholesterol synthesis branch is shown in blue. Flux through the geranylgeranyl-PP/protein prenylation
branch is shown in red. The statin concentration has been selected to ensure that the ﬂux through the cholesterol synthesis branch is the same
as in the multi-drug intervention. (C) Convergence on the optimal multi-drug intervention that suppresses cholesterol synthesis whilst minimizing
off target effects, shown against time and against generations of the genetic algorithm.
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under the general name ‘mevalonic acid’ without unambigu-
ous chemical identiﬁers such as the Simpliﬁed Molecular-
Input Line-Entry System or the International Chemical Iden-
tiﬁer. The isomer form affects the parameterization of the me-
tabolite. Hence, this ambiguity creates potential inaccuracy
in any resulting modelling.
Problem 2: reporting of the wrong data
We found cases of incorrect or incomplete kinetic data reported
in the primary literature that undermined the ability to model
interactions. Vmax values were regularly reported instead of Kcat
values where Vmax is related to Kcat by Vmax = Kcat × (enzyme
concentration). For a Vmax value to be reusable in subsequent
studies, the enzyme concentration must also be reported
alongside it. However, we regularly found this not to be the
case, making most reported Vmax values unusable.
Similarly, inhibitors were frequently parameterized by
IC50 values instead of Ki values, where Ki and IC50 are related
by Ki = IC50/(1 + S/Km) and S is the substrate concentration.
For IC50 values to be reusable in future studies, the substrate
concentrations must also be reported. Here, again, we found
regular omissions that rendered most reported IC50 values
unusable.
Solution (1 and 2): introduce data capture standards that facilitate
unambiguous reconstruction of the results without
optimization. Reporting must include clear and thorough
descriptions of experimental conﬁgurations and
unambiguous identiﬁcation of chemical structures through
the use of comprehensive and standard nomenclature. Past
experience has shown that effective standards can be
developed through open community exercises (e.g. SBML
and SBGN). The necessity for appropriate standards has
been recognized previously by the chemical biology and
pharmacometric communities (Oprea et al., 2011; Swat
et al., 2015).
Standards are already employed widely across the life sci-
ences, frequently building upon ontologies (controlled vo-
cabularies of biological/chemical entities and concepts). The
International Union of Pure and Applied Chemistry, the In-
ternational Union of Biochemistry and Molecular Biology
(IUBMB) Joint Commission on Biochemical Nomenclature
and the Nomenclature Committee of IUBMB have provided
guidelines on biochemical descriptions and enzyme classiﬁ-
cation. A library of ontologies for the life sciences has also
been proposed by the Open Biomedical Ontologies Foundry
(Smith et al., 2007). Standards and guidelines also exist for
reporting biomedical studies, including the minimum infor-
mation (MI) standards overseen by the Minimum Informa-
tion for Biological and Biomedical Investigations Foundry
who include the Standards for Reporting Enzymology Data
Commission (Gardossi et al., 2010). The MI standards of di-
rect relevance include the ‘minimum information about a
bioactive entity’ (Orchard et al., 2011), the ‘minimum infor-
mation about a proteomic experiment’ (Taylor et al., 2007)
and the ‘minimum information about a molecular interac-
tion experiment’ (Orchard et al., 2007).
Problem 3: curation errors
Online databases can contain errors. We have identiﬁed cases
where the incorrect structures, enzyme targets, species and
parameter values had been recorded. Errors were at low fre-
quency, but some would undermine systems pharmacology
approaches, and these fell into two groups: errors that derived
from mistakes in the literature itself, such as from mis-
interpretation of data, and errors that derived from the incor-
rect transcribing from the literature to the database. The for-
mer derive from verbatim acceptance of results from
manuscripts following author error. The latter errors can be
introduced by databases themselves, either from semi-
automated triage tools or inadvertent curator mistakes, and
this can be associated with a lack of clarity in the original
document. In the present study and for the GtoPdb, we
reviewed the primary literature when expanding our datasets
and re-curated existing database coverage.
Solution 3: quality control in curation of results. Using teams of
curators to validate each other’s work can reduce errors. This
can be arranged systematically into error-identifying or error-
correcting curation quality control programmes. In an error-
identifying programme, each result is independently
curated twice and where disagreements are identiﬁed, the
data is reviewed. Such approaches have been discussed
within the International Society for Biocuration (Bateman,
2010). However, the funding limitations of most public
databases preclude this degree of validation. In an error-
correcting programme, each result would be independently
curated three times and where a disagreement is found, the
consensus would be accepted automatically as correct.
Systems pharmacology for the future
A workflow for future studies and hypothesis generation. With
an adequate set of standards and a well-characterized
experimental system, it should be possible to develop
intervention hypotheses that can be tested to inform future
therapy development and to contribute to iterative
reﬁnement of databases. To make this a consistent, high
conﬁdence process, it would be advantageous to work in
one experimental system. Such an experimental system
could be in vivo or in vitro. However, an in vitro model would
offer more control and consistency. Such an in vitro system
would serve as a ﬁrst approximation to in vivo physiology
and would contribute to determining how in vitro
parameters are mapped to in vivo parameters in order to
maximize their value. An advantage of using an in vitro
system is that it would lend itself to automated hypothesis
generation and testing and it could be used to
systematically search for new protein–protein and
drug–target interactions. It has been suggested that artiﬁcial
intelligence methods would be suitable for this purpose in
the laboratory (King et al., 2004). Automation would both
minimize the time required for study and reduce the risk of
misreporting or mis-curating the results.
Our current systems-level understanding has grown to a
scale where manual manipulation is no longer feasible.
Standards such as SBML, SBGN and SBGN-ML and reposito-
ries such as BioModels have been developed partially to ad-
dress this and automated model development allows the full
value of databases to be realized (Swainston et al., 2011).
Open Pharmacological Concept Triple Store (Williams
et al., 2012) is a consortium responsible for a number of
pharmacological and life science databases whose aims
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include the improvement of data availability through the
use of data standards, the incorporation of contextual data
through semantic web standards and the cross-platform
linkage of datasets through an identity mapping service. De-
veloping multi-drug hypotheses is a challenge that grows
exponentially with the number of drugs and interactions
considered. HPC resources are likely to be essential for this
development.
The following workﬂow would enable the process to be
automated (see Figure 3).
(I) Pharmacological literature seeds databases of pharma-
cological interactions.
(II) Pharmacological and chemical databases containing
sufﬁcient information for experimental results to be
reproduced accurately. Database Application Program
Interfaces (APIs) facilitate extraction of results for hy-
pothesis generation.
(III) Interaction literature seeds databases of biological
pathways.
(IV) Pathway databases containing sufﬁcient information
for experimental results to be reproduced accurately.
Database APIs facilitate extraction of results for hypoth-
esis generation.
(V) Hypothesis generation for single drug and multi-drug
interventions using data obtained through APIs from
the pharmacological and pathway databases.
(VI) Hypothesis testing. Success yields a candidate therapy
and provides validation of the database. Failure initiates
further exploration of the underlying interactions that
in turn reﬁne the databases.
(VII) Candidate Intervention. Following success, the group
of compounds enters an optimization pipeline that
reduces them to a minimal set of lead compounds for
preclinical testing to establish their efﬁcacy and safety.
Conclusion
The growth in our understanding of pharmacological
interactions and the continuing development of our ability
to computationally model pathway biology will increasingly
enable us to explore drug combinations that target multiple
points on multiple pathways to reprogram system level
behaviour. In this way, systems pharmacology may lead to
more effective therapies with fewer side effects. Here, we
explored this approach for the mevalonate arm of the
cholesterol biosynthesis pathway, and in doing so, we iden-
tify many of the current barriers to progress.
We attempted to build a systems pharmacology model of
the mevalonate arm of the cholesterol biosynthesis pathway,
but gaps and inconsistencies in the data prevented us from
achieving this to a high level of conﬁdence. In particular, we
Figure 3
The proposed systems pharmacology workﬂow.
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found the lack of comprehensive and systematic parameteriza-
tions, experimental variation, ambiguity in structural detail
and inappropriate and inaccurate reporting from the primary
literature to be obstacles. That this should be the case for a path-
way of such high biomedical and commercial signiﬁcance was
unexpected. For this reason, our best current parameterization
represents a patchwork of values taken from multiple species
and experimental conﬁgurations. Nonetheless, by completing
gaps in our knowledge with representative values, we were able
to demonstrate subtle reprogramming of pathway dynamics
that may contribute signiﬁcantly to drug development. We
propose that these obstacles can be removed through the
adoption of standards and quality control.
Although we focused on the mevalonate arm of choles-
terol biosynthesis, this approach could be applied to any
pathway of interest for which targets and ligands are known.
However, before this can happen at a general level, both the
computational biology and the pharmacology communities
must collaborate to remove the current barriers to progress.
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Figure S1 A sensitivity analysis of pairs of drugs within the
pathway model with colour indicating the degree of pathway
inhibition. Here we plot D = (1-IF/WTF) where IF is the
inhibited ﬂux through the endpoint of the pathway and
WTF is the wild-type ﬂux through the endpoint in the ab-
sence of inhibitors. Green indicates low inhibition (D = 0).
Red indicates high inhibition (D = 1). With eight drugs there
are seventy–two possible pairings. These six heat map plots
have been selected as being representative of the results.
The IC10, IC20, IC30, IC40, IC50, IC50, IC60, IC70, IC80
and IC90 were identiﬁed for each drug in isolation. We then
combined pairs of drugs at these concentrations and
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evaluated their effects by calculating the resulting D value.
Values of D with both drugs at IC10 are bottom left and with
both drugs at IC90 are top right. For Rosuvastatin the IC10-
IC90 concentrations were (4.2, 10.9, 20.7, 35.1, 56.1, 87.7,
138.0, 228.3, 442.7) nM; for Farnesyl Thiodiphosphate the
IC10-IC90 concentrations were (325.4, 732.1, 1255, 1952,
2929, 4393, 6833, 11 716, 26 360) nM; for Cinnamic acid
the IC10-IC90 concentrations were (27829629.8,
62617146.82, 107344511.7, 166981644.3, 250474415.3,
375714567.5, 584449515.1, 1 001 921 461, 2 254 341 919)
nM and for Zaragozic acid A the IC10-IC50 concentrations
were (0.5, 0.9, 1.3, 1.7, 2.1, 2.6, 3.3, 4.3, 6.4) nM.
Figure S2 A representative reaction from the mevalonate
arm of the cholesterol biosynthesis pathway, as described on
the IUPHAR/BPS GuidetoPharmacology (GtoPdb).
Table S1 The publicly available pathway and chemical data-
bases used.
Table S2 The inhibitors used in the model of the pathway
with structural information. The inhibitors selected were
those with the greatest efﬁcacy in humans.
Table S3 The ten best performing drug combinations identi-
ﬁed using the genetic algorithm as part of hypothesis genera-
tion, together with their scores.
File S1 Supplementary_Mevalonate_Pathway.sbgn A biolog-
ically meaningful, machine readable SBGN ﬁle encoding the
diagram shown in Figure 1.
File S2 Supplementary_Mevalonate_Pathway.sbml A biolog-
ically meaningful, machine readable SBML ﬁle encoding
the mathematical model describing the pathway shown in
Figure 1.
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